-
Mar 5, 2020 Apotex Statement: Drug Supply and COVID-19
-
Sep 20, 2018 ACCC announces clearance of the merger of Arrow Pharmaceuticals & Apotex Australia & NZ merger
-
Jul 14, 2018 Apotex Focuses on High Growth Markets with Sale of European Generics Business
-
Jun 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
-
May 9, 2018 Apotex Announces Proposed Merger of AUS & NZ Operations
-
Jun 12, 2017 Apobiologix Applauds Supreme Court Decision in Sandoz Biosimilar Case
-
Jun 8, 2017 Canadian Scientists Honored for Role in Breakthrough Drug
-
Apr 28, 2017 University of Saskatchewan, Apotex renew partnership with $1.6M donation to the College of Pharmacy and Nutrition
-
Mar 8, 2017 Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company's Largest Investment in the United States
-
Mar 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
-
Mar 24, 2016 Apotex Launches First Generic Version of Merck's Nasonex®
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.